Skip to main content
An official website of the United States government

Sleep Hygiene Education, ReadiWatchTM Actigraphy and Telehealth Cognitive Behavioral Training for Insomnia for Symptom Relief in Men with Prostate Cancer Receiving Androgen Deprivation Therapy, SHERE-Relief 2 Trial

Trial Status: complete

This clinical trial evaluates the effectiveness of wearing a ReadiWatch, trademark, actigraphy for sleep hygiene education and telehealth cognitive behavioral training for insomnia (teleCBT-I) to improve symptoms of insomnia in men with prostate cancer receiving androgen deprivation therapy. Many treatments, such as androgen deprivation therapy, for prostate cancer can cause significant fatigue and/or problems with memory and concentration and can also result in disturbed sleep. Improving sleep may reduce feelings of fatigue and improve memory and concentration. The ReadiWatch is a wearable device that provides real-time feedback on sleep patterns, instructions on how to improve sleep, and a score that indicates periods of time when fatigue and issues with memory and concentration may be troublesome. Behavioral interventions, such as teleCBT-I, use techniques to help patients change the way they react to environmental triggers that may cause a negative reaction. A ReadiWatch together with teleCBT-I may improve sleep and quality of life in men with prostate cancer receiving androgen deprivation therapy.